Specify a stock or a cryptocurrency in the search bar to get a summary
Inventiva Sa
IVEVFInventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France. Address: 50 rue de Dijon, Daix, France, 21121
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IVEVF
Dividend Analytics IVEVF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IVEVF
Stock Valuation IVEVF
Financials IVEVF
Results | 2019 | Dynamics |